Abstract | BACKGROUND: AIMS: METHODS: The present analysis shows the findings of 1377 patients with New York Heart Association (NYHA) class II-III CHF who received diuretic therapy with torasemide 10 mg/day orally (n=778) vs. patients who received furosemide 40 mg/day orally (n=527) or other diuretics (n=72) on top of their existing standard CHF therapy for 12 months. Besides safety and tolerability, efficacy was assessed by documentation of mortality, morbidity, functional class and serum potassium levels every 3 months. RESULTS: TORIC confirmed the safety and tolerability of torasemide in CHF patients. Mortality was significantly lower in the torasemide (n=17, 2.2%) than in the furosemide/other diuretics group (n=27, 4.5%) (P<0.05). Functional improvement as assessed by NYHA class was observed in more patients who received furosemide torasemide (n=356, 45.8%) than those who received furosemide/other diuretics (n=223, 37.2%) (P=0.00017). At the end of the study abnormally low serum potassium levels were observed in fewer torasemide (n=95, 12.9%) than furosemide/other diuretics patients (n=102, 17.9%) (P=0.013). CONCLUSION:
Torasemide is safe and well tolerated in CHF patients. Although not designed as a mortality study, TORIC suggests a lower mortality amongst CHF patients treated with torasemide compared to furosemide/other diuretics. A functional improvement and a lower incidence of abnormal serum potassium levels were also observed in patients receiving torasemide as compared to those receiving furosemide/other diuretics.
|
Authors | Juan Cosín, Javier Díez, TORIC investigators |
Journal | European journal of heart failure
(Eur J Heart Fail)
Vol. 4
Issue 4
Pg. 507-13
(Aug 2002)
ISSN: 1388-9842 [Print] England |
PMID | 12167392
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
- Diuretics
- Sulfonamides
- Furosemide
- Potassium
- Torsemide
|
Topics |
- Aged
- Chronic Disease
- Diuretics
(adverse effects, therapeutic use)
- Female
- Furosemide
(adverse effects, therapeutic use)
- Heart Failure
(drug therapy, mortality, physiopathology)
- Humans
- Male
- Middle Aged
- Potassium
(blood)
- Product Surveillance, Postmarketing
- Stroke Volume
(drug effects, physiology)
- Sulfonamides
(adverse effects, therapeutic use)
- Survival Rate
- Torsemide
- Treatment Outcome
- Ventricular Function, Left
(drug effects, physiology)
|